Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced Synthetic Methods in Modern Medicinal Chemistry.

Journal of medicinal chemistry·2026
Same author

Targeting dihydroorotate dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor.

European journal of medicinal chemistry·2026
Same author

Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH).

European journal of medicinal chemistry·2026
Same author

Fluorescent Isostere (<i>Fluostere</i>) of the Carboxylate: Design of <i>h</i>DHODH Fluorescent Inhibitors as Proof of Concept.

Journal of medicinal chemistry·2025
Same author

An adamantane-based ligand as a novel chemical tool for thermosensory TRPM8 channel therapeutic modulation.

The FEBS journal·2025
Same author

Chalcone Synthesis by Green Claisen-Schmidt Reaction in Cationic and Nonionic Micellar Media.

The Journal of organic chemistry·2025

Related Experiment Video

Updated: Jul 13, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

New potential uroselective NO-donor alpha1-antagonists.

Donatella Boschi1, Gian Cesare Tron, Antonella Di Stilo

  • 1Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Turin, Italy.

Journal of Medicinal Chemistry
|August 9, 2003
PubMed
Summary

New nitric oxide-donor alpha(1)-antagonists were developed by combining a uroselective drug with NO-donor groups. These compounds effectively target the alpha(1a)-receptor subtype and relax smooth muscle tissue.

More Related Videos

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 13, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Urology

Background:

  • Alpha(1)-adrenoceptor antagonists are used in treating lower urinary tract symptoms.
  • Nitric oxide (NO) plays a role in smooth muscle relaxation.
  • Combining these properties could lead to novel therapeutic agents.

Purpose of the Study:

  • To synthesize and characterize novel NO-donor alpha(1)-antagonists.
  • To evaluate their selectivity for the alpha(1a)-receptor subtype.
  • To assess their functional activity in smooth muscle relaxation.

Main Methods:

  • Synthesis of novel compounds incorporating NO-donor moieties (nitrooxy, furoxan) with a uroselective alpha(1)-antagonist (REC15/2739).
  • Radioligand binding assays to determine receptor affinity and selectivity for human cloned alpha(1a)-adrenoceptors.
  • In vitro functional assays using isolated rat vas deferens to assess relaxation responses.

Main Results:

  • All synthesized compounds demonstrated potent and selective antagonism of the human alpha(1a)-adrenoceptor.
  • Derivatives 6 and 7 exhibited significant relaxation of the prostatic portion of rat vas deferens.
  • This relaxation was attributed to both alpha(1A)-antagonist activity and NO-donor properties.

Conclusions:

  • Novel NO-donor alpha(1)-antagonists targeting the alpha(1a)-receptor subtype have been successfully developed.
  • These compounds possess dual mechanisms of action, combining receptor antagonism with NO-mediated smooth muscle relaxation.
  • This suggests potential therapeutic applications in conditions involving alpha(1)-adrenoceptor overactivity and smooth muscle dysfunction.